Cytosorbents's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cytosorbents's ROA in the second quarter of 2026?
Cytosorbents Corporation recorded a cumulative net loss of $-18 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -43.25%.

However, within the Healthcare sector 518 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3575, from total ROA ranking in the first quarter of 2026 at 3992.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-20.9 %	-20.12 %	9.56 %	24.09 %	10.63 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-18	-12	-8	-11	-10
Return On Assets (TTM)	-43.25 %	-26.55 %	-17.38 %	-22.91 %	-22.16 %
CTSO's Total Ranking	# 3575	# 3992	# 3585	# 3585	# 3878
Total Assets (TTM) in million	38	41	44	46	48
Seq. Total Assets Change	-6.41 %	-8.19 %	-3.43 %	-4.67 %	-5.5 %
Seq. Net Income Change	-	-	-	-	-

CTSO's 5 Years Annual ROA >> Back to CTSO Management Effectiveness >> Compare CTSO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 138
Sector	# 519
Overall	# 3804

Return On Assets Statistics
High	Average	Low
-10.34 %	-58.85 %	-141.12 %
(Mar 31 2021)		(Sep 30 2013)

News about Cytosorbents Corporation Return on Assets ROA

CytoSorbents Embarks on Canadian Approval Journey for DrugSorb-ATR Amid Financial Challenges

CytoSorbents Corporation, a critical care immunotherapy company specialising in blood purification technology, has recently taken a significant step forward in its global expansion efforts. The company announced the submission of its DrugSorb-ATR Medical Device License Application to Health Canada. This milestone submission follows the successful completion of the Medical Device Single Audit Program (MDSAP) certification, which underscores the company’s compliance with international standards for medical device manufacturing and quality systems.The DrugSorb-ATR is a cutting-edge blood purification device designed to remove specific inflammatory molecules and toxins from the bloodstream, making it a potentially vital tool in the treatment of numerous medical conditions. If approved by Health Canada, DrugSorb-ATR could become an essential component in the Canadian healthcare market, providing clinicians with an innovative tool to enhance patient treatment outcomes.

CytoSorbents Secures $20 Million Credit Facility to Support Regulatory and Commercialization Goals

In a significant development for medical device company CytoSorbents, the company recently announced securing a $20 million credit facility, providing them with a valuable injection of non-dilutive capital to accelerate their regulatory and commercialization objectives. This crucial funding comes at a time when the company s stock has reached its 52-week low, signifying a need for financial support to navigate future growth.
The credit facility represents a major milestone for CytoSorbents as it seeks to drive forward its innovative medical solutions and expand its market presence. The funding injection will support the company s regulatory efforts, enabling it to undergo necessary clinical trials, secure regulatory clearances, and accelerate the pace at which it can introduce its groundbreaking technologies to market.

Financial Statements
Cytosorbents's Assets	$ 38 million	CTSO's Balance sheet
Cytosorbents's Income	$ -4 million	Quarterly CTSO's Income Statement
CTSO's Income by Division		See CTSO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	20.7 %	-12.34 %	-20.46 %	-31.32 %	-13.69 %
Total Assets in million	44	37	42	53	76
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-8	-21	-29	-33	-25
Annual Return On Assets	-18.56 %	-56.6 %	-68.27 %	-62.5 %	-32.12 %

CTSO's 5 Years Annual ROA >> Back to CTSO Management Effectiveness >> Compare CTSO ROA to its Competitors

More Return On Assets Ratios
CTSO's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CTSO's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CTSO's Competitors
Subscribers only: Roa for Cytosorbents's Suppliers
Subscribers only: Return On Assets for CTSO's Customers

You may also want to know
CTSO's Roi	CTSO's Inventory Turnover Ratio	CTSO's Growth Rates	CTSO's Dividend Comparisons
	CTSO's Profitability Ratios	CTSO's Asset Turnover Ratio	CTSO's Dividend Growth
CTSO's Roe	CTSO's Valuation Ratios	CTSO's Financial Strength Ratios	CTSO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:43:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.